USPTO Patent Application for CsgA-Derived Nanostructures for Antigen Delivery
Summary
The USPTO has published a patent application (US20260083834A1) for CsgA-derived nanostructures designed for antigen delivery. The application details self-assembling polypeptides conjugated to immunogens that form nanofilaments to stimulate immune responses, potentially for vaccines against various conditions.
What changed
This document is a publication of a United States Patent Application (US20260083834A1) filed by inventors Steve Bourgault et al. The application describes novel self-assembling polypeptides derived from the CsgA protein, which can be conjugated to immunogens. These conjugates self-assemble into nanofilaments capable of activating humoral and cellular immune responses, with potential applications in vaccines for preventing or treating microbial infections, cancer, autoimmune diseases, and allergies.
This is a patent application, not a regulatory rule or enforcement action. It does not impose new compliance obligations on regulated entities. However, it is relevant for pharmaceutical and biotechnology companies involved in vaccine development and antigen delivery systems. Companies in this space may wish to review the application for potential intellectual property insights or competitive intelligence regarding novel approaches to immune response stimulation.
Archived snapshot
Mar 26, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
CsgA-DERIVED NANOSTRUCTURES AND USES THEREOF FOR ANTIGEN DELIVERY
Application US20260083834A1 Kind: A1 Mar 26, 2026
Inventors
Steve BOURGAULT, Denis ARCHAMBAULT, Dominic ARPIN, Felix LAMONTAGNE
Abstract
Purified antigens are usually weakly immunogenic and require the addition of immunostimulatory agents and/or delivery systems to generate robust antigen-specific responses. The present application relates to self-assembling polypeptides that may be conjugated to immunogens and have the ability to self-assemble into immunogen-displaying nanofilaments that activate the humoral and cellular immune responses. The self-assembling polypeptide comprises an amino acid sequence having at least 60% identity with the sequence of the R4 and R5 domains from a Curli-specific gene A (CsgA) protein. The present application also relates to nucleic acids encoding the self-assembling polypeptide/immunogen conjugates, to compositions and vaccines comprising the self-assembling polypeptide/immunogen conjugates or nucleic acids, as well as to methods for inducing an immune response against an immunogen and/or for preventing and/or treating a microbial infection, cancer or any pathological conditions in which vaccination may be useful such as autoimmune diseases and allergies, in a subject.
CPC Classifications
A61K 39/145 A61P 37/04 C07K 14/005 C07K 14/24 A61K 2039/55505 A61K 2039/6031 C12N 2760/16122 C12N 2760/16134 C12N 2760/16171
Filing Date
2023-09-06
Application No.
19109453
Named provisions
Related changes
Get daily alerts for USPTO Patent Applications - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.